Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks

Hypogonadism Clinical Trial

Official title:

A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00710827
• Other study ID #: 91579
• Secondary ID: 2008-002053-2031
• Status: Withdrawn
• Phase: Phase 4
• First received: July 2, 2008
• Last updated: November 22, 2012
• Start date: October 2008
• Est. completion date: October 2008

Study information

• Verified date: November 2012
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesItaly: The Italian Medicines AgencyUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsRussia: Ministry of Health of the Russian FederationLatvia: State Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of Nebido compared to placebo in elderly men aged 50 and over with symptomatic late onset hypogonadism

Description:

Explorative objectives: Change in grip strength (Subgroup only: optional for sites with experienced in testing muscle function); Change in physical performance test i.e. lower limb muscle strength (subgroup only; optional for sites experienced in testing muscle function). Please note that the 2 explorative objectives mentioned above must be performed together. All measured at baseline, week 30, week 54, no safety measure. Safety parameters Prostate safety: digital rectal examination (DRE) Measured at screening, week 30+ 54, safety measure. International prostate symptom score (IPSS): International prostate symptom score (IPSS) Measured at screening, week 18, 30, 42, 54, safety measure. Laboratory tests for lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) and liver function tests (aspartate aminotransferase (AST) and alanine transaminase (ALT)) Measured at screening, week 6, 18, 30, 42, 54, safety measure. Standard laboratory tests for androgen treatment: prostate specific antigen (PSA); hemoglobin; hematocritMeasured at screening, week 6, 18, 30, 42, 54, safety measureAdverse eventsMeasured at screening, baseline, week 6, 18, 30, 42, 54Vital signsMeasured at screening, week 18, 30, 42, 54, safety measure.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Men aged 50 years and older

• Symptomatic hypogonadism as defined by a) and b):

• a) Total testosterone below 12nmol/l

• b) Aging males symptom score above 36

• Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study

• Willing to voluntarily sign a statement of informed consent to participate in the study.

Exclusion Criteria:

• Use of androgen therapy or anabolic steroids

• Suspicion or known history of liver tumors, prostate or breast cancer

• Hypersensitivity to the active substances or any of the excipients of NEBIDO e.g. Benzyl benzoate and castor oil. Hypercalcemia accompanying malignant tumors

• Blood coagulation irregularities presenting an increased risk of bleeding after intramuscular injections sleep apnea

• Polycythemia

• Hematocrit level >50% at entry to the study (i.e. screening visit/visit 1)

• Patients using 5-a-reductase inhibitors such as finasteride or dutasteride should be excluded from the study.

• Prolactin level >25ng/ml

• Organic hypothalamic-pituitary pathology

• Prostate specific antigen (PSA) level = 4ng/ml

• Severe symptomatic benign prostatic hyperplasia (IPSS sum score = 20)

• Epilepsy not adequately controlled by treatment

• Migraine not adequately controlled by treatment

• Patients requiring or undergoing fertility treatment

• Any clinically significant chronic disease that might, in the opinion of the investigator, compromise patient's safety interfere with the evaluations, or preclude completion of the trial (e.g. hemochromatosis, chronic lung disease, chronic malabsorption disease)

• Known history of alcohol or drug abuse

• Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study.

• Hypertension which is not adequately controlled on therapy

• Severe cardiac, hepatic or renal insufficiency

• Coronary heart disease not stabilized by therapy as assessed by the investigator

• Metal implants in the body (metal implants in the head will not exclude patients from participation)

• Concomitant participation in another clinical trial within 1 month of entry into this study (i.e. randomized and has taken study medication).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypogonadism

Intervention

Drug:
• NEBIDO
Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
• PLACEBO
Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Germany,  Italy,  Latvia,  Poland,  Russian Federation,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the change from baseline in lean body mass after 54 weeks of treatment with NEBIDO compared to placebo		Baseline, week 30, week 54	No
Secondary	Change from baseline in total body mass		Baseline, week 30, week 54	No
Secondary	Change from baseline in fat mass		Baseline, week 30, week 54	No
Secondary	Change from baseline in bone mineral density		Baseline, week 30, week 54	No
Secondary	Aging Male Symptoms (AMS) rating scale		Baseline, week 30, week 54	No
Secondary	International Index of Erectile Function- erectile function domain (IIEF-EF)		Baseline, week 30, week 54	No
Secondary	Change in serum levels of testosterone (central laboratory)		Baseline, week 30, week 54	No
Secondary	Change in waist circumference		Baseline, week 30, week 54	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.